Sector News

Non-exec director appointment at ConvaTec

June 22, 2017
Life sciences

Reading-headquartered medical products and technology company ConvaTec has added to its board with a new non-executive director appointment.

Dr Ros Rivaz has taken up her new position as a non-executive director of the company with immediate effect.

Her non-executive board experience spans FTSE 100, large private and not-for-profit organisations. Rivaz served as a non-executive director and chairman of the remuneration committee at Rexam prior to its acquisition by Ball Corporation in 2016, and currently sits on the board of RPC Group, Computacenter, Ministry of Defence Equipment and Support and is also vice chair of the council of Southampton University, among other roles.

Previously, Rivaz held a range of senior executive management roles across major FTSE100 and international businesses. From 2011 to 2014 she was global chief operating officer of Smith & Nephew, having previously served in senior operations, manufacturing and supply chain roles at Premier Foods, Diageo, ICI and Tate & Lyle.

Sir Christopher Gent, chairman of ConvaTec, said: “I am delighted to welcome Ros to the Board of ConvaTec. She brings exceptional and significant experience gained from a successful career across a variety of industries.

“Ros has a detailed understanding of the medical products and technology sector, and she will make a valuable contribution to ConvaTec. The board looks forward to working closely with her.”

Earlier this month, Nordic Capital and Avista agreed to sell 250 million shares in ConvaTec to institutional investors at a price of 322p per share, raising gross proceeds of £805m, through an accelerated bookbuilding process.

By Muhammad Aldalou

Source: Insider Media

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach